Alaunos Therapeutics | ZIOP - Operating Expenses


Alaunos Therapeutics reported $1.01M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bioline Rx USD 2.63M 24K Sep/2025
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Celltrion KRW 140.68B 584.31B Dec/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Cspc Pharmaceutical CNY 5.91B 512.77M Dec/2025
Curis USD 9.02M 23.01M Dec/2025
Deva Holding AS TRY 1.35B 178.26M Sep/2023
Dianthus Therapeutics USD 69.82M 29.14M Dec/2025
Divis Laboratories Ltd INR 20.17B 1.85B Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 364M 54M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Kangmei Pharma CNY 1.09B 304.02M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 21.61M 11.59M Dec/2025
Merck USD 18.17B 8.01B Mar/2026
Neuren Pharmaceuticals AUD 25.23M 16.54M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Organigram Holdings CAD 83.66M 24.44M Dec/2025
Ovoca Bio EUR 1.16M 4.48M Jun/2025
Pfizer USD 90.1B 77.19B Mar/2026
Pharma Mar EUR 42.28M 4.59M Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Qiagen NV USD 418.54M 23.25M Dec/2025
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sartorius EUR 738.4M 22.4M Mar/2026
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
TG Therapeutics USD 170.12M 28.04M Mar/2026
Tilray USD 237.52M 17.34M Sep/2025
Verastem USD 59.01M 21.98M Dec/2025
Zealand Pharma A/S 775.97M 265.08M Dec/2025
Zz Pientze Pharmaceu CNY 1.88B 326.34M Mar/2026